Wire · opportunities
FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Locally Advanced or ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
The FDA has approved zanidatamab in combination with chemotherapy, with or without tislelizumab, as a first-line treatment for HER2-positive locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, based on the phase 3 HERIZON-GEA-01 trial showing significant improvements in progression-free and overall survival compared to trastuzumab plus chemotherapy.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 25 Aug 2026 and 8 Sep 2026.
◆ ◆ The Wire takeaway
You face a new competitor standard in frontline HER2-positive gastric cancer that rivals trastuzumab-based regimens. Review your clinical partnerships and adjust your pipeline ambitions against in-market effectiveness for combination therapies involving zanidatamab and chemotherapy.
◆ Coverage
10 sources · first reported 25 Aug 2026 · latest 8 Sep 2026
◆ Related on Wire
◆ Topics